High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Kim, Ekaterina [1 ]
Sivina, Mariela [1 ]
Vaca, Alicia [1 ]
Ferrajoli, Alessandra [1 ]
Jain, Nitin [2 ]
Thompson, Philip A. [1 ]
Wierda, William G. [1 ]
Wodarz, Dominik [3 ]
Chiorazzi, Nicholas [4 ]
Burger, Jan A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] Feinstein Inst Med Res, Karches Ctr Oncol Res, Manhasset, NY USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-160238
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4140 / 4141
页数：2
相关论文
共 50 条
  • [1] Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib
    Burger, Jan A.
    Li, Kelvin W.
    Keating, Michael J.
    Sivina, Mariela
    Amer, Ahmed M.
    Garg, Naveen
    Ferrajoli, Alessandra
    Huang, Xuelin
    Kantarjian, Hagop
    Wierda, William G.
    O'Brien, Susan
    Hellerstein, Marc K.
    Turner, Scott M.
    Emson, Claire L.
    Chen, Shih-Shih
    Yan, Xiao-Jie
    Wodarz, Dominik
    Chiorazzi, Nicholas
    JCI INSIGHT, 2017, 2 (02):
  • [2] Pharmacokinetics (PK) of ibrutinib in patients with chronic lymphocytic leukemia (CLL)
    Sukbuntherng, Juthamas
    Jejurkar, Purvi
    Chan, Stephen
    Tran, Anh L.
    Moussa, Davina
    James, Danelle Frances
    Loury, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL)
    Nicholas Wright
    Ensi Voshtina
    Gemlyn George
    Arun Singavi
    Joshua Field
    International Journal of Hematology, 2019, 110 : 751 - 755
  • [4] Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL)
    Wright, Nicholas
    Voshtina, Ensi
    George, Gemlyn
    Singavi, Arun
    Field, Joshua
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 751 - 755
  • [5] High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy
    Fleury, Carole
    Quinquenel, Anne
    Fornecker, Luc-Matthieu
    Ysebaert, Loic
    Thieblemont, Catherine
    Zini, Jean-Marc
    Feugier, Pierre
    Willems, Lise
    Collon, Jean-Francois
    Eclache, Virginie
    Lazarian, Gregory
    Letestu, Remi
    Cymbalista, Florence
    Baran-Marszak, Fanny
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S217 - S218
  • [6] Hypertension in ibrutinib-treated patients with chronic lymphocytic leukemia (CLL)
    Roeker, Lindsey
    Yazdy, Maryam
    Gashonia, Lisa
    Narkhede, Mayur
    Goodfriend, Julie
    Rhodes, Joanna
    Kennard, Kaitlin
    Dorsey, Colleen
    Sarmasti, Lisa
    Calivo, Kathleen
    Carver, Joseph
    Schuster, Steven
    Cheson, Bruce D.
    Mato, Anthony
    LEUKEMIA & LYMPHOMA, 2020, 61 : 55 - 56
  • [7] Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)
    Akhtar, Othman S.
    Attwood, Kristopher
    Lund, Ian
    Hare, Ryan
    Hernandez-Ilizaliturri, Francisco J.
    Torka, Pallawi
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1650 - 1655
  • [8] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
    Burger, J. A.
    Tedeschi, A.
    Barr, P. M.
    Robak, T.
    Owen, C.
    Ghia, P.
    Bairey, O.
    Hillmen, P.
    Bartlett, N. L.
    Li, J.
    Simpson, D.
    Grosicki, S.
    Devereux, S.
    McCarthy, H.
    Coutre, S.
    Quach, H.
    Gaidano, G.
    Maslyak, Z.
    Stevens, D. A.
    Janssens, A.
    Offner, F.
    Mayer, J.
    O'Dwyer, M.
    Hellmann, A.
    Schuh, A.
    Siddiqi, T.
    Polliack, A.
    Tam, C. S.
    Suri, D.
    Cheng, M.
    Clow, F.
    Styles, L.
    James, D. F.
    Kipps, T. J.
    Keating, Michael
    Jen, Jie
    Jindra, Pavel
    Simkovic, Martin
    Braester, Andrei
    Ruchlemer, Rosa
    Foa, Roberto
    Semenzato, Gianpietro
    Hawkins, Timothy
    Atanasio, Carolina Moreno
    Demirkan, Fatih
    Kaynar, Leylagul
    Pylypenko, Halyna
    Fox, Christopher
    Thirman, Michael
    Campbell, Philip
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25): : 2425 - 2437
  • [9] Chronic lymphocytic Leukemia (CLL) Ibrutinib in the First Line: Standard for High-risk Patients
    Pickl, Susanne
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (1-2) : 76 - 76
  • [10] Phase Ib Study of Ianalumab (VAY736) and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
    Rogers, Kerry A.
    Flinn, Ian W.
    McGarry, Carolyn
    Gou, Liangke Connie
    Hassounah, Nadia
    Woo, Janghee
    Byrd, John C.
    BLOOD, 2020, 136
12345